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Abstract UDP-glucuronosyltransferase 1A6 (UGT1A6) is a 
membrane glycoprotein of the endoplasmic reticulum playing a 
key role in drug metabolism. It is synthesized as a precursor with 
an N-terminal cleavable signal peptide. We demonstrate that 
deletion of the signal peptide sequence does not prevent 
membrane targeting and integration of this human isoform when 
expressed in an in vitro transcription-translation system, as 
shown by N-glycosylation, resistance to alkaline treatment and 
protease protection. Furthermore, UGT1A6 lacking the signal 
peptide (UGT1A6Asp) was targeted to the endoplasmic reticulum 
in mammalian ceils as shown by immunofluorescence microscopy 
and was catalytically active with kinetic constants for 4- 
methylumbelliferone glucuronidation similar to that of the wild- 
type. These results provide evidence that the signal peptide is not 
essential for the membrane assembly and activity of UGTIA6 
suggesting that additional topogenic element(s) mediate(s) this 
process. 
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Key words: UDP-glucuronosyltransferase; Signal peptide; 
Endoplasmic reticulum targeting; Membrane translocation; 
Human 
1. Introduction 
Most eukaryotic proteins which are translocated across the 
endoplasmic reticulum (ER) membrane are synthesized as pre- 
cursors with a N-terminal signal sequence (for review see [1]). 
Integral membrane proteins possess in addition a 'stop trans- 
fer' sequence which prevents complete translocation and sta- 
bly anchors the protein into the membrane [2]. Single mem- 
brane-spanning proteins with a cleavable signal peptide 
usually have an N-terminal side of the transmembrane do- 
main localized in the lumen and the C-terminal portion ex- 
posed on the cytoplasmic side. UDP-glucuronosyltransferases 
(UGTs, EC 2.4.1.17) are predicted to present such a type I 
topology with the amino-terminus and the majority of the 
protein located at the lumenal face of the ER. These proteins 
are anchored to the membrane via a single C-terminal trans- 
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membrane domain followed by a short cytoplasmic tail. The 
proposed transmembrane topology of UGTs has been essen- 
tially constructed on computer-based predictions. Experimen- 
tal evidence using rat and human liver microsomes as well as 
recombinant enzymes confirm the general features of this 
model, but in the absence of available X-ray crystallography, 
this model remains hypothetical [3,4]. 
UGTs are members of a superfamily of glycosyltransferases 
that catalyze the conjugation of a variety of hydrophobic 
aglycone substrates with glucuronic acid donated by UDP- 
glucuronic acid [5]. This reaction results in the formation of 
a hydrosoluble J3-D-glucuronide that is easily excreted into bile 
or urine. Thus, these enzymes are centrally involved in the 
metabolism and detoxication of drugs, pollutants and toxic 
substances [6]. UGT1A6 is a human isoform encoded by the 
UGT1 locus, which is expressed predominantly in the liver but 
also in kidney and other extrahepatic tissues [7]. It is respon- 
sible for the conjugation of planar phenols such as 4-methyl- 
umbelliferone (4-MU), drugs (paracetamol, naftazone [8,9]) or 
environmental carcinogens such as chrysene and benzo[a]pyr- 
ene derived phenols [10]. The individual specificity of each 
UGT isoform towards aglycone substrates is provided by 
the N-terminal domain that represents the major region of 
dissimilarity between UGTs [11]. The high degree of sequence 
conservation i the C-terminal half of UGT proteins uggests 
that this domain is involved in the binding of the common 
cosubstrate, UDP-glucuronic acid. 
Towards a detailed understanding of the mechanisms of 
membrane assembly of UGTs which are critical for the strtSc- 
ture and the function of these enzymes, we decided to inves- 
tigate the role of the cleavable N-terminal signal peptide se- 
quence of UGT1A6. A previous tudy designed to address the 
influence of exchanging the eukaryotic signal peptide with 
bacterial counterparts suggested that the enzyme deprived of 
its signal peptide (UGT1A6Asp) was nevertheless associated 
with the membrane fraction of recombinant Es'cherichia coli 
[12]. In this report, we investigate the role of the cleavable N- 
terminal signal peptide in the ER membrane targeting of 
UGT1A6 in an in vitro transcription-translation system and 
in recombinant mammalian cells. Interestingly, we found that 
the signal peptide of UGT1A6 is not required either for the 
ER subcellular localization or for the functional integrity of 
the enzyme. 
Abbreviations: DMEM, Dulbecco's modified Eagle's medium; ER, 
endoplasmic reticulum; 4-MU, 4-methylumbelliferone; PBS, phos- 
phate buffer saline; PCR, polymerase chain reaction; SDS-PAGE, 
sodium dodecylsulfate-polyacrylamide gel electrophoresis; UGT, 
UDP-glucuronosyltransferase 
2. Materials and methods 
2.1. Materials 
UDP-[U-14C]glucuronic a id (300 mCi/mmol) and [35S]methionine 
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PII: S0014-5793(99)00797-8  
188 
(100 mCi/mmol) were obtained from NEN. Restriction enzymes, T4 
DNA ligase, RNAsin and pGEM-3Z were purchased from Promega. 
The plasmid pcDNA3.1 was from Invitrogen. Vent DNA polymerase 
was provided by Biolabs. All other reagents, including Geneticin 
(G418), proteinase K, 4-MU (free acid) and 4-MU-glucuronide were 
purchased from Sigma. The acceptor tripeptides N-benzoyl-Asn-Asn- 
Thr-N-methylamide and N-benzoyl-Asn-Ala-Ser-N-methylamide were 
synthesized by Dr. G. Bloomberg (Recognition Centre Peptide Syn- 
thesis Facility, Bristol, UK) and used as competitive inhibitors of 
asparagine-linked glycosylation as previously described [13]. 
2.2. Plasmid constructions 
Cloning and sequencing of full-length UGT1A6 cDNA (GenBank 
data base access number M84130) have been reported previously [14]. 
For the in vitro transcription-translation experiments, UGT1A6 
cDNA was subcloned into the SmaI site of pGEM-3Z under the 
control of the T7 promoter. For the expression i mammalian cells, 
this sequence was subcloned into HindIII-XbaI sites of the pCDNA3.1 
eukaryotic expression vector as described [7]. 
UGT1A6 cDNA encoding the protein lacking the 26 N-terminal 
amino acids corresponding to the signal peptide sequence (UG- 
T1A6Asp) was generated by polymerase chain reaction (PCR) using 
a 5' primer corresponding to amino acid residues 27 33 of the pre- 
protein with an attached Kozak sequence and a HindIII site. The 3' 
primer was complementary to the sequence ncoding the last five 
amino acid residues and the stop codon with an Xbal attached site. 
PCR amplification was carried out using UGT1A6 cDNA as tem- 
plate. The resulting PCR product was ligated into the Sinai site of 
pGEM-3Z for in vitro transcription-translation studies. 
A second construct in which 62 bp of the 5' untranslated region of 
UGTIA6 cDNA was attached upstream to the sequence encoding the 
protein lacking the signal peptide (UGTIA6Asp) was generated by 
simple overlapping ends PCR amplification using appropriate oligo- 
nucleotides [15]. The resulting fragment was subcloned into the Sinai 
site of pGEM-3Z under the control of the T7 promoter for in vitro 
transcription-translation studies. Finally, the latter sequence, ncoding 
UGT1A6Asp, was subcloned into HindIII-XbaI sites of pcDNA3.1 
expression vector and the recombinant plasmid was used for expres- 
sion in mammalian cells. All mutant clones were screened for Taq- 
introduced errors by dideoxy sequencing [16]. 
2.3. In vitro protein synthesis 
The recombinant pGEM-3Z plasmids encoding the full-length 
UGT1A6 and its counterpart lacking the signal peptide 
(UGT1A6Asp) were linearized at the XbaI restriction site localized 
downstream of the TAG stop translation codon. These linearized 
plasmids erved as templates for in vitro transcription by T7 RNA 
polymerase coupled to translation i a rabbit reticulocyte lysate using 
the TNT Coupled Reticulocyte Lysate kit (Promega). The reactions 
were carried out at 30°C for 60 rain in the presence of [35S]methionine. 
The radiolabeled transcription-translation products were then ana- 
lyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) [17]. For membrane insertion tests, canine pancreas 
microsomal membranes (Promega) were added to the transcription- 
translation mixture before the addition of T7 RNA polymerase ac- 
cording to the suggestions of the supplier. The canine pancreas micro- 
somal membranes u ed in this study were assayed for signal peptidase 
and N-glycosylation activities using two different control mRNAs, the 
precursor for ]3-1actamase from E. coli and the precursor for c~-mating 
factor from Saccharomyees cerevisiae, respectively, as described by the 
supplier (Promega). N-Glycosylation of newly synthesized polypepti- 
des (full-length UGT1A6 and UGTIA6Asp) was tested by addition of 
competitive glycosylation acceptor tripeptides (0.2 raM) in the tran- 
scription-translation mixture. These tripeptides mimic each of the two 
potential asparagine-linked glycosylation sites of UGTIA6 (aspara- 
gine 293 and 345). For alkaline extraction, the incubation mixture 
containing the microsomes was diluted two times in buffer A 
(50 mM potassium acetate, 200 mM sodium carbonate, 20 mM tri- 
ethanolamine, 1 mM magnesium acetate, pH 11.5). The reaction mix- 
ture was kept in ice for 20 min and layered over 250 gl buffer B 
(0.25 M sucrose, 50 mM triethanolamine, 140 mM potassium acetate, 
2.5 mM magnesium acetate) containing 100 mM sodium carbonate, 
pH 11.5. Microsomes were sedimented at 100000×g in a Sorva11 RC 
MI20 micro-ultracentrifuge for 20 rain. The pellet was washed with 
25 gl of buffer B and suspended in gel loading buffer. Supernatant 
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proteins were precipitated with trichloroacetic a id (10% (v/v)) and the 
samples were electrophoresed on 10% (w/v) SDS-polyacrylamide g ls 
[17]. The protease sensitivity of the expressed polypeptides was ana- 
lyzed using proteinase K (0.2 mg/ml) at 0°C for 30 min as described 
by Connolly et al. [18]. The samples were heated at 100°C in Laemmli 
sample buffer prior to SDS-PAGE. Dried gels were exposed irectly 
to Kodak Biomax film for visualization. 
2.4. Heterologous expression i  mammalian cells" 
V79 cells (Chinese hamster lung fibroblasts) were cultured in Dul- 
becco's modified Eagle's medium (DMEM, Gibco-BRL) supple- 
mented with 8% (v/v) Nu-Serum (Becton-Dickinson) and antibiotics. 
Transfection and stable expression were carried out as previously 
described [19]. For each transfection, 30 colonies were screened for 
in situ 4-MU-glucuronide production, as described below. The colony 
expressing the highest level of 4-MU glucuronidation activity was 
selected and cultured in the conditions described above. 
2.5. Immunoftuorescence microscopy 
Immunofluorescence wascarried out on V79 cells stably expressing 
UGT1A6 or UGT1A6Asp. Cells were cultured for 24 h in 30 mm 
diameter wells on coverslips, fixed with 3% (w/v) para-formaldehyde 
in phosphate buffer saline (PBS, Gibco-BRL) and permeabilized with 
0.4% (w/v) saponin/PBS followed by blocking with 0.2% (w/v) gelatin/ 
PBS. Permeabilized cells were then incubated for 1 h with polyclonal 
anti-UGT1A6 antibodies [7]. These antibodies were raised against the 
120 N-terminal amino acid residues of UGT1A6 protein expressed in
E. coli, and have been shown to be highly specific towards the 
UGT1A6 isoform [7]. The cells were then washed with PBS and in- 
cubated for 20 rain with fluorescein isothiocyanate-conjugated secon- 
dary antibodies (Sigma). For double immunofluorescence staining, the 
same procedure was repeated using monoclonal nti-calnexin primary 
antibodies provided by Affinity Bioreagents Inc. This antibody was 
raised against a human calnexin protein, a typical ER resident protein 
classically used as a marker for this organelle [20]. In this case, poly- 
clonal anti-mouse IgG rhodamine-conjugated antibodies (Sigma) were 
used as secondary antibodies. Finally, cells were washed in PBS, 
mounted on microscopy slides and examined by fluorescence micros- 
copy using a Zeiss Axiophot microscope with a 100 × objective. 
2.6. Preparation of membrane nriched fi'action of recombinant cells 
amt enzymatic assays 
The measurement of in situ 4-MU-glucuronide formation in re- 
combinant V79 cells was performed as previously described [21]. 
The amount of 4-MU-glucuronide r leased into the culture medium 
was quantitated by fluorescence spectroscopy [22]. 
The preparation of the membrane enriched fraction of recombinant 
V79 cells was performed as previously described [21]. Protein concen- 
tration was measured according to Bradford [23] with Bio-Rad re- 
agent (Bio-Rad). Glucuronidation of 4-MU in membrane fraction 
and in supernatant of the 100 000 ×g centrifugation was assayed as 
previously reported [22]. Apparent kinetic constants for the glucuro- 
nidation of 4-MU in membrane fractions were calculated by linear 
least squares regression analysis of values from double-reciprocal 
plots corresponding to at least six different concentrations of substrate 
(0.05 5 raM) at a constant concentration of UDP-glucuronic acid (5 
raM). 
3. Results 
3.1. In vitro translocation and processing o f  UGT1A6 expressed 
with and n'ithout signal peptide 
In vitro transcription-translation in the presence of pan- 
creas microsomal membranes is a powerful tool routinely 
used to study the targeting, translocation, post-translational 
modifications and membrane insertion of proteins [24-26]. 
This system was thus used to study the cleavage of the N- 
terminal signal peptide and asparagine-linked glycosylation, 
which are the only post-translational modifications described 
for UGTs as well as the membrane insertion of UGT1A6 [27]. 
In vitro transcription of UGT IA6  coupled to translation in 
a reticulocyte lysate resulted in the synthesis of a single 54 kDa 
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Fig. 1. In vitro expression of the cDNAs encoding the precursor 
and mature form of UGT1A6. UGTIA6 and UGT1A6Asp were 
transcribed and translated in a reticulocyte lysate system in the ab- 
sence (lanes 1 and 2, respectively) or in the presence of dog pan- 
creas microsomes (lanes 3 and 4, respectively). Acceptor tripeptides 
were used as inhibitors of N-linked glycosylation of UGT1A6 and 
UGTIA6Asp synthesized in the presence of membranes (lanes 5 and
6, respectively). Microsomal membranes containing UGTIA6 and 
UGT1A6Asp were subjected to carbonate extraction and fractio- 
nated by centrifugation on a sucrose cushion to yield pellet (P, anes 
7 and 8, respectively) and supernatant (S, lanes 9 and 10, respec- 
tively) fractions. Microsomal membranes containing UGT1A6 and 
UGT1A6Asp were subjected to treatment by proteinase K as de- 
scribed in Section 2 (lanes 11 and 12, respectively). The 35S-radiola- 
belled products were analyzed by SDS-PAGE and subjected to 
autoradiography. 
polypeptide corresponding to the expected apparent molecular 
mass for the preprotein UGT1A6 (Fig. 1, lane 1). The addi- 
tion of canine pancreas microsomes to the reaction mixture 
produced slower-migrating polypeptides of about 55 56 kDa 
corresponding to the cleavage of the signal peptide followed 
by N-asparagine linked glycosylation (Fig. 1, lane 3). Con- 
sistently, the addition to the reaction mixture of tripeptides 
that prevent he N-glycosylation abolished the observed shift, 
yielding a single polypeptide band of 52 kDa corresponding to 
the mature unglycosylated form of UGTIA6 (Fig. 1, lane 5). 
An attempt was made to express UGT1A6Asp from the 
UGT1A6 sequence deleted from both the 5' untranslated re-
gion and the signal peptide coding sequence. However, a very 
small amount of the corresponding polypeptide was yielded. 
We therefore designed a second construct in which the UG- 
TIA6Asp sequence was placed downstream of the 5' untrans- 
lated region of the wild-type UGT1A6 cDNA. In this case, in 
vitro expression was successful, giving rise to a polypeptide of 
the expected apparent molecular mass of about 52 kDa (Fig. 
1, lane 2). Interestingly, in the presence of microsomal mem- 
branes, the apparent molecular mass of the neosynthesized 
polypeptide was increased by about 2 kDa (Fig. 1, lane 4). 
This decrease of mobility was abolished by addition of glyco- 
sylation inhibitory tripeptides (Fig. 1, lane 6), indicating that 
the deletion mutant was translocated and N-glycosylated in 
the lumen of the ER. Furthermore, UGT1A6 lacking the sig- 
nal peptide as well as the wild-type protein were found to be 
stably integrated into the microsomal membranes. Indeed, the 
majority of UGT1A6 and of UGT1A6Asp polypeptides was 
recovered in the pellet fraction (Fig. 1, lanes 7, 8, respectively) 
whereas tiny amounts of protein could be detected in the 
supernatant (Fig. 1, lanes 9, 10, respectively) following treat- 
ment with sodium carbonate. Finally, UGT1A6 and UG- 
T IA6Asp polypeptides were treated with proteinase K. As 
shown in Fig. 1, both the wild-type UGT1A6 (lane 11) and 
the deletion mutant (lane 12) were protected against proteol- 
ysis. Based on these criteria, our results established that 
UGT1A6 deprived of its N-terminal cleavable signal peptide 
was targeted, translocated and integrated into the ER mem- 
brane in an apparently identical orientation, compared to the 
wild-type protein. 
3.2. Targeting of UGT1A6 expressed with or without signal 
peptide in mammalian cells' 
We next investigated the subcellular localization of UG- 
TIA6Asp compared to the wild-type protein by immunofluo- 
rescence microscopy after stable expression in V79 cells. In 
cells expressing UGT1A6, a typical ER fluorescence pattern 
(Fig. 2A), similar to that of calnexin, an integral membrane 
protein used as ER marker (Fig. 2B), was observed. Interest- 
ingly, like the wild-type protein, UGT1A6Asp was found to be 
localized in the ER (Fig. 2C) with an immunofluorescence 
pattern overlapping that of calnexin (Fig. 2D). These obser- 
vations show that, despite the absence of signal peptide, 
UGT1A6 was addressed to the ER in mammalian cells. 
3.3. UGT1A6 lacking the signal peptide is" functionally 
expressed in mammalian cells' 
The ex vivo assay was based on the measurement of the 
amount of glucuronides produced and excreted after addition 
of the substrate 4-MU into the culture medium. After 24 h, 
about 44_+ 6 nmol and 39 + 4 nmol of 4-MU-glucuronide were 
produced per l06 cells in the extracellular medium of cultured 
UGT1A6 and UGT1A6Asp V79 cells, respectively, while less 
than 1 nmol was produced by non-transfected cells during the 
same time period. 
Evaluation of the glucuronidation of 4-MU in the mem- 
brane enriched fraction and in the 100000×g supernatant 
of UGT1A6 and UGT1A6Asp V79 cells showed that the en- 
zymatic activity was exclusively found in the membrane frac- 
tion of both recombinant cells. The apparent Km and Vmax 
values for 4-MU catalyzed by UGT1A6Asp (0.55 + 0.17 raM, 
8.39+ 1.23 nmol/min/mg protein, respectively) in the mem- 
brane enriched fractions were in the same range as those ob- 
tained for the native recombinant protein (0.61 +0.19 raM, 
11.14 + 2.11 nmol/min/mg protein, respectively). Similar ob- 
servations were found when the kinetics of 1-naphthol was 
considered (results not shown). 
4. Discussion 
We report, for the first time, that a type I integral ER 
membrane protein, the human UGT1A6, was targeted, trans- 
located into and retained in the ER in the absence of its N- 
terminal cleavable signal peptide. This result was based on 
several lines of evidence. (1) UGT1A6 lacking the signal pep- 
tide expressed in vitro in a transcription-translation system 
was glycosylated as the wild-type protein, indicating that in 
both cases the N-glycosylation sites have been translocated 
across the microsomal membranes. (2) UGT1A6Asp remained 
associated with the pelleted fraction following alkaline xtrac- 
tion, suggesting that, like the wild-type protein, the polypep- 
tide was stably integrated into the microsomal membranes. (3) 
Both the deletion mutant and the wild-type UGT1A6 synthe- 
sized in vitro in the presence of membranes were protected 
from protease degradation suggesting a lumenal orientation of 
both polypeptides. (4) Immunofluorescence studies illustrated 
that, despite the lack of signal peptide, UGT1A6 stably ex- 
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Fig. 2. Intracellular localization of UGTIA6 expressed with and without signal peptide in V79 cells. Immunofluorescence detection of UGT1A6 
(A) and UGT1A6Asp (C) was performed in cells stably expressing each polypeptide using a primary polyclonal anti-UGT1A6 antibody and a 
F1TC-conjugated secondary antibody. Immunofluorescence detection of calnexin was subsequently performed on the same V79 UGT1A6 (B) 
and V79 UGT1A6Asp cells (D), using anti-calnexin primary antibodies and rhodamine-conjugated secondary antibodies. 
pressed in mammalian cells was addressed to and retained in 
the ER. 
Interestingly, UGT1A6Asp was fully active as shown by the 
in situ production of 4-MU-glucuronide, which was not sig- 
nificantly different from that measured with the wild-type pro- 
tein. Furthermore, the glucuronidation activity with 4-MU as 
substrate was associated with the microsomal fraction and 
exhibited apparent kinetic constants similar to UGT1A6. 
These results indicate that the mutant was correctly folded 
and retained a tertiary structure allowing a normal substrate 
recognition and catalytic activity. 
The role of the signal peptide in the initiation of the trans- 
location process has been well documented [1]. In general, 
mutations and deletions within the signal peptide sequence 
result in a strong inhibition of the translocation process lead- 
ing to the accumulation of the protein in the cytosol or to its 
degradation [28]. However, the observation that the natural 
cleavable N-terminal signal sequence can be entirely removed 
without precluding the translocation of secretory or mem- 
brane proteins across the ER, as for UGT1A6, is not without 
precedent. It has been clearly shown that despite the absence 
of its N-terminal signal sequence, the yeast alkaline phospha- 
tase could be translocated across the ER membrane in vivo or 
in vitro [29]. In the same way, Loo et al. [30] recently reported 
for the human Na+-Ca z+ exchanger, an integral plasma mem- 
brane polytopic protein, that despite the lack of a signal pep- 
tide sequence, the protein was addressed to its normal sub- 
cellular localization and fully functional, when expressed in 
mammalian cells. 
For UGTIA6  and other proteins that tolerate a deletion of 
the signal peptide, the role of this sequence may therefore be 
questioned. One possibility is that it may enhance membrane 
insertion. In fact, it has been reported that thedeletion of the 
signal peptide reduced the efficiency of secretion of alkaline 
phosphatase in whole cells [31]. In the same way, it has been 
demonstrated that the fusion of a cleavable signal peptide to 
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the human ~32-adrenergic receptor increased the translocation 
of the receptor into the ER [32]. It can be suggested that such 
an increase would enhance the expression of the protein in cell 
types which express low levels of the protein, but would not 
be detectable in the high levels of expression achieved in V79 
cells. Similarly to our data, Loo et al. [30] did not observe any 
reduced efficiency in the expression of Na+-Ca 2+ exchanger 
expressed without signal peptide in mammalian cells. 
Xu et al. [33] recently demonstrated that bacteriorhodopsin 
made without a 13 residue leader peptide was properly as- 
sembled in the membrane. However, deletion of the leader 
region resulted in an unstable mRNA and almost no bacter- 
iorhodopsin production. It is noteworthy that in the absence 
of the untranslated region, UGT1A6Asp was inefficiently ex- 
pressed in vitro in contrast to the wild-type protein. It is 
therefore possible to speculate that the signal peptide could 
contribute to the efficiency of translation and/or mRNA 
stability. 
In summary, data obtained from expression of UGT1A6 in 
vitro as well as in mammalian cells clearly showed that the 
signal peptide sequence is not essential for ER targeting and 
functionality of this protein. The most likely explanation for 
these observations i the presence of redundant topogenic el- 
ements capable of directing the protein deprived of signal 
peptide to the ER membrane. In fact, cooperativity between 
topogenic elements has recently been described for several 
polytopic plasma membrane protein such as band 3 anion 
exchanger [26], or sodium calcium exchanger [30]. Computer 
prediction of secondary structures reveals the presence of hy- 
drophobic stretches in the N-terminal half of UGT1A6 that 
may interact with the membranes. The topogenic role of these 
putative signal-like sequences i under investigation. 
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